Executive Summary

Azoth Analytics has released a research report titled “Idiopathic Pulmonary Fibrosis Market (2023 Edition)” which provides a complete analysis of the global Idiopathic Pulmonary Fibrosis industry in terms of market segmentation by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 11 countries (United States, Canada, Mexico, United Kingdom, Germany, France, Italy, China, India, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

During the forecast period, 2024-2029, the Global Idiopathic Pulmonary Fibrosis market is expected to expand at a CAGR of 46.3%. The Global Idiopathic Pulmonary Fibrosis Market is expected to generate USD 10.64 billion by the end of 2029, up from USD 4.39 billion in 2022.

IPF is a life-threatening illness and is both progressive and incurable. Treatments can manage symptoms, limit disease progression, and improve quality of life. Pirfenidone and nintedanib are authorized IPF treatments that slow fibrosis. Severe instances may require lung transplants.

Although IPF is considered a rare disease, its incidence has increased over time. It is estimated that 13 to 20 people per 100,000 are affected globally. The prevalence is higher in older age categories, and the disease is diagnosed more frequently in people over 50. IPF affects both men and women, although men are slightly more susceptible. Ongoing research and clinical trials are investigating novel treatments and potential IPF therapies. Among these are antifibrotic agents, immunomodulatory drugs, and other novel therapeutic approaches that target different pathways implicated in the fibrotic process.

IPF patients need medical follow-ups. Work with interstitial lung disease specialists to create a specific treatment plan and support methods. IPF is characterized by a persistent dry cough, shortness of breath (especially during physical activity), exhaustion, and chest pain. These symptoms typically develop and worsen over time.

Scope of the Report:

  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
  • The report presents the analysis of the Idiopathic Pulmonary Fibrosis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, Other drugs).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Route of Administration (Oral, Parenteral, Other ROA).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, F. Hoffmann-La Roche AG, Cipla Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Co., United Therapeutics, FibroGen, Inc., Pliant Therapeutics, Galecto Inc., CSL Behring